EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

Zubida M Al-Majdoub iD, Martyn Howard, Brahim Achour iD, Jill Barber iD, Naved Alizai, Amin Rostami-Hodjegan iD

Clinical Pharmacology & Therapeutics · 2026-06 · 119 (6) · 1584-1596

DOI: 10.1002/cpt.70244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 04.03.2026. Verfasst von Zubida M Al-Majdoub und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Biliary Atresia, Liver. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric populations differ from adults in drug elimination capacity. While current scaling methods account for enzyme and transporter maturation, they overlook comorbidities, such as biliary atresia (BA), a liver disease appearing within the first 2–8 weeks of life that can progress to cirrhosis. Such conditions may impair hepatic drug clearance, requiring dose adjustments. Physiologically based pharmacokinetic (PBPK) tools aim to address such cases and have been advocated to fill gaps in clinical data instead of less formalized and evidence‐based guesswork. However, the paucity of systems data in rare disease populations has hindered the development of robust PBPK models. This study used global liquid chromatography and tandem mass spectrometry (LC–MS/MS) proteomics to quantify drug‐metabolizing enzymes and transporters in diseased neonatal ( n = 13) and infant ( n = 12) liver samples, revealing significant expression changes in biliary atresia (BA) livers vs. controls ( n = 19). Based on cohort means, CYP2A6, CYP2B6, and CYP2E1 levels were 6–17‐fold higher in BA livers compared to controls, while CYP4F11 and CYP20A1 were reduced. UGT1A1, UGT2B4, and UGT2B7 showed up to 16‐fold higher abundance in neonates with BA. Among transporters, ABCF1 abundance increased dramatically (46‐fold), whereas B3AT/SLC4A1, ADT1/SLC25A4, and S27A5/SLC27A5 were decreased. The observed alterations suggest that assuming similar liver function in BA and non‐BA patients has implications, with impact varying by drug clearance pathway. While in silico models can explore this, clinical pharmacokinetic studies in BA are essential for verification. To our knowledge, such studies are absent. Our observations underscore the urgent need for dedicated pharmacokinetic studies in BA patients to improve precision dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary AtresiaLiverHumansInfant, NewbornInfantTandem Mass SpectrometryFemaleProteomicsMaleChromatography, LiquidCytochrome P-450 Enzyme System

Substanzen

Cytochrome P-450 Enzyme System

Autor:innen und Institutionen

  • Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, Manchester, UK.
  • Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, the University of Rhode Island, Kingston, Rhode Island, USA.
  • Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Certara Predictive Technologies, Certara Inc, Sheffield, UK.

ORCID-Profile: Zubida M Al-Majdoub, Brahim Achour, Jill Barber, Amin Rostami-Hodjegan

Zitieren

APA

Al-Majdoub, Z. M., Howard, M., Achour, B., Barber, J., Alizai, N., & Rostami-Hodjegan, A. (2026). Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia. Clinical Pharmacology & Therapeutics, 119(6), 1584-1596. https://doi.org/10.1002/cpt.70244

Vancouver

Al-Majdoub ZM, Howard M, Achour B, Barber J, Alizai N, Rostami-Hodjegan A. Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia. Clinical Pharmacology & Therapeutics. 2026;119(6):1584-1596. doi:10.1002/cpt.70244

BibTeX
@article{AlMajdoub2026,
  author = {Al-Majdoub, Zubida M and Howard, Martyn and Achour, Brahim and Barber, Jill and Alizai, Naved and Rostami-Hodjegan, Amin},
  title = {Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {6},
  pages = {1584--1596},
  doi = {10.1002/cpt.70244}
}
Kostenlos starten →